Published on the occasion of an exhibition held at the Walker Art Center. Minneapolis, Minn., Feb. 27-May 23, 2010.

This book is a thorough, practical review of the challenges facing clinicians treating skin microbes and how to combat these therapeutic dilemmas. It expresses the critical public health concern of antimicrobial resistance and shows how microorganisms are developing the ability to halt the progress of antimicrobials like antibiotics, antivirals, and antifungals. Chapters are grouped together in five sections for ease of use. The first three sections of the book convey foundational information on the mechanisms of antibiotics, antivirals, and antifungals resistance, as well as the implications of lack of vaccination. The fourth section then turns to the specifics of drug resistance for protozoan and helminth infections focusing primarily on initial and subsequent resistance to treatment. The book closes with a discussion on the potential solutions of innovative therapy including new delivery mechanisms, broad-spectrum antibiotics, phytocompounds, and biofilms. Chapters feature magnified, microscopic photos for identifying structures as they appear on the skin. Part of the Updates in Clinical Dermatology series, Overcoming Antimicrobial Resistance of the Skin is an important resource relevant during the COVID-19 pandemic, and is written for all medical healthcare professionals.

Leading experts summarize and synthesize the latest discoveries concerning the changes that occur in tumor cells as they develop resistance to anticancer drugs, and suggest new approaches to preventing and overcoming it. The authors review physiological resistance based upon tumor architecture, cellular resistance based on drug transport, epigenetic changes that neutralize or bypass drug cytotoxicity, and genetic changes that alter drug target molecules by decreasing or eliminating drug binding and efficacy. Highlights include new insights into resistance to antiangiogenic therapies, oncogenes and tumor suppressor genes in therapeutic resistance, cancer stem cells, and the development of more effective therapies. There are also new findings on tumor immune escape mechanisms, gene amplification in drug resistance, the molecular determinants of multidrug resistance, and resistance to taxanes and Herceptin.

Includes: Scientific proceedings of the Society of American Bacteriologists.